{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:33:58Z","timestamp":1791588838709,"version":"4.3.4"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cholangiocarcinoma (CCA), a highly aggressive biliary tract malignancy, exhibits rising incidence rates and an extremely poor prognosis. Recent studies reveal that gut-liver axis dysregulation drives CCA progression through gut microbiota dysbiosis, bile acid (BA) metabolic disturbances, and immune microenvironment remodeling. Clinical evidence highlights significant alterations in the gut and biliary microbial composition of CCA patients, which correlate with tumor stage, vascular invasion, and survival outcomes. Dysregulated BA metabolism in CCA, characterized by accumulation of primary conjugated BAs, promotes tumor invasiveness via interaction with specific BA receptors and fosters an immunosuppressive microenvironment. Emerging therapeutic strategies include antibiotics for pathogenic microbiota modulation, probiotics for microbial homeostasis restoration, fecal microbiota transplantation, and BA pathway modulators. Future directions necessitate integrating synthetic biology (engineered microbiota), multi-omics, and artificial intelligence to develop precision therapies. Targeting the gut-liver axis offers novel therapeutic perspectives for CCA; however, clinical translation demands deeper mechanistic insights and standardized protocols to address challenges such as microbiota heterogeneity and receptor signaling duality.<\/jats:p>","DOI":"10.3389\/fonc.2025.1646897","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:16:12Z","timestamp":1757650572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions"],"prefix":"10.3389","volume":"15","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj234","article-title":"Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States","volume":"98","author":"Welzel","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"24","author":"Massarweh","year":"2017","journal-title":"Cancer Control."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist."},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0987-3","article-title":"Current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"123","author":"Marin","year":"2020","journal-title":"Br J Cancer."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.64","article-title":"Quality of life, long-term survivors and long-term outcome from the ABC-02 study","volume":"114","author":"Bridgewater","year":"2016","journal-title":"Br J Cancer."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01383","article-title":"SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: Pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2019.10.11","article-title":"Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma","volume":"9","author":"Herraez","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167152","article-title":"Gut microbiota regulates the ALK5\/NOX1 axis by altering glutamine metabolism to inhibit ferroptosis of intrahepatic cholangiocarcinoma cells","volume":"1870","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29683","article-title":"Lipopolysaccharide promotes cancer cell migration and invasion through METTL3\/PI3K\/AKT signaling in human cholangiocarcinoma","volume":"10","author":"Ke","year":"2024","journal-title":"Heliyon."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002672117","article-title":"JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma","volume":"117","author":"Manieri","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0304","article-title":"Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12967-024-06012-x","article-title":"Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids","volume":"23","author":"Lederer","year":"2025","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12072-021-10279-3","article-title":"Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer","volume":"16","author":"Deng","year":"2022","journal-title":"Hepatol Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01890-9","article-title":"Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice","volume":"10","author":"Wang","year":"2025","journal-title":"Nat Microbiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.molcel.2020.03.001","article-title":"Immune-microbiota interplay and colonization resistance in infection","volume":"78","author":"Leshem","year":"2020","journal-title":"Mol Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut."},{"key":"B27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cmet.2019.08.002","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"30","author":"Loomba","year":"2019","journal-title":"Cell Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103003","article-title":"Inflammation and the gut-liver axis in the pathophysiology of cholangiopathies","volume":"19","author":"Giordano","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11092363","article-title":"Gut microbiota in diagnosis, therapy and prognosis of cholangiocarcinoma and gallbladder carcinoma-A scoping review","volume":"11","author":"Lederer","year":"2023","journal-title":"Microorganisms."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215379","article-title":"Dysbiosis of the fecal and biliary microbiota in biliary tract cancer","volume":"14","author":"Ito","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.751795","article-title":"A predictive model based on the gut microbiota improves the diagnostic effect in patients with cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/hep.30852","article-title":"Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma","volume":"71","author":"Jia","year":"2020","journal-title":"Hepatology."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i18.3497","article-title":"Association between gut microbiota and hepatocellular carcinoma and biliary tract cancer: A mendelian randomization study","volume":"12","author":"Zhang","year":"2024","journal-title":"World J Clin Cases."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1288525","article-title":"Elucidating the causal association between gut microbiota and intrahepatic cholangiocarcinoma through Mendelian randomization analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1090392","article-title":"Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijsu.2018.05.027","article-title":"Visceral infiltration of intrahepatic cholangiocarcinoma is most prognostic after curative resection - Retrospective cohort study of 102 consecutive liver resections from a single center","volume":"55","author":"Bartsch","year":"2018","journal-title":"Int J Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34372","article-title":"Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2119055","article-title":"Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling","volume":"14","author":"Li","year":"2022","journal-title":"Gut Microbes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3920\/bm2020.0057","article-title":"Short chain fatty acids in human gut and metabolic health","volume":"11","author":"Blaak","year":"2020","journal-title":"Benef Microbes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/ecosalplus.ESP-0001-2018","article-title":"Function and biogenesis of lipopolysaccharides","volume":"8","author":"Bertani","year":"2018","journal-title":"EcoSal Plus."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15899","article-title":"The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review","volume":"37","author":"Pohl","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11020267","article-title":"Endotoxemia and gastrointestinal cancers: insight into the mechanisms underlying a dangerous relationship","volume":"11","author":"Manilla","year":"2023","journal-title":"Microorganisms."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012661","article-title":"Role of intestinal microbes in chronic liver diseases","volume":"23","author":"Xu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604942","article-title":"Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system","volume":"100","author":"Killeen","year":"2009","journal-title":"Br J Cancer."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16235","article-title":"Liver GPBAR1 associates with immune dysfunction in primary sclerosing cholangitis and its activation attenuates cholestasis in abcb4-\/- mice","volume":"45","author":"Di Giorgio","year":"2025","journal-title":"Liver Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2023.104.1.10","article-title":"Incidence of bactibilia and related factors in patients who undergo cholecystectomy","volume":"104","author":"Moon","year":"2023","journal-title":"Ann Surg Treat Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/idr.S200378","article-title":"The microbiota of the bilio-pancreatic system: a cohort, STROBE-compliant study","volume":"12","author":"Di Carlo","year":"2019","journal-title":"Infect Drug Resist"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294049","article-title":"Microbial profile in bile from pancreatic and extra-pancreatic biliary tract cancer","volume":"19","author":"Di Carlo","year":"2024","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1038\/s41598-021-82378-y","article-title":"Bacterial bile duct colonization in perihilar cholangiocarcinoma and its clinical significance","volume":"11","author":"Bednarsch","year":"2021","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.cgh.2022.09.006","article-title":"Bile duct colonization with enterococcus sp. Associates with disease progression in primary sclerosing cholangitis","volume":"21","author":"Zigmond","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2021.117","article-title":"Antibiotic-resistant bacteria colonizing the bile duct are associated with increased morbidity and mortality after resection of extrahepatic cholangiocarcinoma","volume":"23","author":"Cammann","year":"2022","journal-title":"Surg Infect (Larchmt)."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome","volume":"486","year":"2012","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00488-6","article-title":"Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities","volume":"21","author":"Hajishengallis","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41579-024-01075-5","article-title":"The oral-gut microbiome axis in health and disease","volume":"22","author":"Kunath","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4526","article-title":"Ectopic colonization of oral bacteria in the intestine drives T(H)1 cell induction and inflammation","volume":"358","author":"Atarashi","year":"2017","journal-title":"Science."},{"key":"B63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40779-022-00423-x","article-title":"Alterations in the human oral microbiome in cholangiocarcinoma","volume":"9","author":"Rao","year":"2022","journal-title":"Mil Med Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12967-024-05989-9","article-title":"Metagenomic characterization of oral microbiome signatures to predict upper gastrointestinal and pancreaticobiliary cancers: a case-control study","volume":"23","author":"Oh","year":"2025","journal-title":"J Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2020.108757","article-title":"Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism","volume":"165","author":"Chen","year":"2021","journal-title":"Steroids."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.Mcr-13-0503","article-title":"Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development","volume":"12","author":"Lozano","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.4.1367","article-title":"Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice","volume":"16","author":"Sombattheera","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6763","article-title":"Diagnostic value of serum bile acid composition patterns and serum glycocholic acid levels in cholangiocarcinoma","volume":"14","author":"Proungvitaya","year":"2017","journal-title":"Oncol Lett"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2020.105775","article-title":"Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls","volume":"205","author":"Zhang","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5371381","article-title":"Investigation of 23 bile acids in liver bile in benign and Malignant biliary stenosis: A pilot study","volume":"2019","author":"Rejchrt","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13588","article-title":"The role of bile acid subtypes in the diagnosis of cholangiocarcinoma","volume":"18","author":"Wang","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.762781","article-title":"Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway","volume":"31","author":"Dai","year":"2013","journal-title":"Cancer Invest."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2939","article-title":"Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR\/ERK1\/2 signaling pathway","volume":"46","author":"Amonyingcharoen","year":"2015","journal-title":"Int J Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J Med Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000491715","article-title":"FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting IL-6-induced epithelial-mesenchymal transition","volume":"48","author":"Lv","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8964","article-title":"FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-021-00035-2","article-title":"Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer","volume":"2","author":"Girisa","year":"2021","journal-title":"Mol Biomed"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1159\/000490019","article-title":"Allicin inhibits proliferation and invasion in vitro and in vivo via SHP-1-mediated STAT3 signaling in cholangiocarcinoma","volume":"47","author":"Chen","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1159\/000450917","article-title":"Role of the G protein-coupled bile acid receptor TGR5 in liver damage","volume":"35","author":"Reich","year":"2017","journal-title":"Dig Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation","volume":"65","author":"Reich","year":"2016","journal-title":"Vivo vitro. Gut."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/jm7015864","article-title":"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies","volume":"51","author":"Sato","year":"2008","journal-title":"J Med Chem"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.668277","article-title":"Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line","volume":"290","author":"Liu","year":"2015","journal-title":"J Biol Chem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27085","article-title":"Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1186\/s12885-024-13081-0","article-title":"Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma","volume":"24","author":"Deng","year":"2024","journal-title":"BMC Cancer."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2003","article-title":"A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer","volume":"6","author":"Farhat","year":"2022","journal-title":"Hepatol Commun"},{"key":"B88","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol Rev"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.12.011","article-title":"Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases","volume":"12","author":"Guan","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123709","article-title":"Bile acids and GPBAR-1: dynamic interaction involving genes, environment and gut microbiome","volume":"12","author":"Portincasa","year":"2020","journal-title":"Nutrients."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16495","article-title":"Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis","volume":"119","author":"Thomas","year":"2000","journal-title":"Gastroenterology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science."},{"key":"B95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ajpath.2024.11.004","article-title":"Gut microbiome and bile acid interactions: mechanistic implications for cholangiocarcinoma development, immune resistance, and therapy","volume":"195","author":"Wu","year":"2025","journal-title":"Am J Pathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30975","article-title":"Probiotic lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbrc.2019.09.103","article-title":"Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury","volume":"520","author":"Ren","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107275","article-title":"Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis","volume":"206","author":"Hu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/nu15234864","article-title":"Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways","volume":"15","author":"Han","year":"2023","journal-title":"Nutrients."},{"key":"B100","doi-asserted-by":"publisher","first-page":"12324","DOI":"10.1038\/s41598-019-48784-z","article-title":"Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice","volume":"9","author":"Cabrera-Rubio","year":"2019","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03150-24","article-title":"Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice","volume":"13","author":"Xie","year":"2025","journal-title":"Microbiol Spectr."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000406","article-title":"The role of the gut microbiome in the development of hepatobiliary cancers","volume":"80","author":"Daniel","year":"2024","journal-title":"Hepatology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010133","article-title":"Antibiotic exposure concurrently with anti-PD1 blockade therapy reduces overall survival in patients with child-pugh class A advanced hepatocellular carcinoma","volume":"16","author":"Alshammari","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1451170","article-title":"Lactiplantibacillus plantarum inhibited the growth of primary liver cancer by inducing early apoptosis and senescence","volume":"15","author":"Duduyemi","year":"2024","journal-title":"vitro. Front Microbiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2390176","article-title":"Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion","volume":"16","author":"Wu","year":"2024","journal-title":"Gut Microbes"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118804","article-title":"Si-Ni-San ameliorates cholestatic liver injury by favoring P","volume":"337","author":"Li","year":"2025","journal-title":"goldsteinii colonization. J Ethnopharmacol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772532","article-title":"Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota","volume":"12","author":"Gao","year":"2021","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-21-0808","article-title":"A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota","volume":"12","author":"Messaoudene","year":"2022","journal-title":"Cancer Discov"},{"key":"B114","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MAJ.0b013e31823aace6","article-title":"Preoperative probiotics decrease postoperative infectious complications of colorectal cancer","volume":"343","author":"Zhang","year":"2012","journal-title":"Am J Med Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40792-021-01216-5","article-title":"Probiotic-related bacteremia after major hepatectomy for biliary cancer: a report of two cases","volume":"7","author":"Shimura","year":"2021","journal-title":"Surg Case Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620967898","article-title":"A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group","volume":"9","author":"Keller","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041683","article-title":"Research progress of fecal microbiota transplantation in liver diseases","volume":"12","author":"Zhao","year":"2023","journal-title":"J Clin Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095392","article-title":"FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial","volume":"15","author":"Al-Shakhshir","year":"2025","journal-title":"BMJ Open"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2476561","article-title":"Dysregulation of gut microbiota stimulates NETs-driven HCC intrahepatic metastasis: therapeutic implications of healthy faecal microbiota transplantation","volume":"17","author":"Deng","year":"2025","journal-title":"Gut Microbes"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111855","article-title":"TGR5 promotes cholangiocarcinoma by interacting with mortalin","volume":"389","author":"Li","year":"2020","journal-title":"Exp Cell Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/cells13191650","article-title":"Bile acids-based therapies for primary sclerosing cholangitis: current landscape and future developments","volume":"13","author":"Fiorucci","year":"2024","journal-title":"Cells."},{"key":"B124","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12964-025-02224-w","article-title":"Inhibition of Farnesoid-x-receptor signaling during abdominal sepsis by dysbiosis exacerbates gut barrier dysfunction","volume":"23","author":"Qian","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B125","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.08.006","article-title":"ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis","volume":"374","author":"Yao","year":"2024","journal-title":"J Control Release."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"18873","DOI":"10.1038\/s41598-022-23539-5","article-title":"Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210077","article-title":"The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma","volume":"14","author":"Di Matteo","year":"2019","journal-title":"PloS One"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-020-02819-w","article-title":"Farnesoid X receptor antagonizes Wnt\/\u03b2-catenin signaling in colorectal tumorigenesis","volume":"11","author":"Yu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.11.031","article-title":"HNF4 regulates fatty acid oxidation and is required for renewal of intestinal stem cells in mice","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1197063","article-title":"Structural insights into the HNF4 biology","volume":"14","author":"Beinsteiner","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1412709","article-title":"Targeting gut-microbiota for gastric cancer treatment: a systematic review","volume":"11","author":"Marashi","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"B139","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/microbiolspec.BAD-0020-2017","article-title":"Engineering diagnostic and therapeutic gut bacteria","volume":"5","author":"Landry","year":"2017","journal-title":"Microbiol Spectr."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1998.5606","article-title":"Structure and chromosomal assignment of the sterol 12alpha-hydroxylase gene (CYP8B1) in human and mouse: eukaryotic cytochrome P-450 gene devoid of introns","volume":"56","author":"G\u00e5fvels","year":"1999","journal-title":"Genomics."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.73","article-title":"Human tumor xenografts: the good, the bad, and the ugly","volume":"20","author":"Morgan","year":"2012","journal-title":"Mol Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmx009","article-title":"Butyrate: A double-edged sword for health","volume":"9","author":"Liu","year":"2018","journal-title":"Adv Nutr"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308341","article-title":"Geographical patterns of the standing and active human gut microbiome in health and IBD","volume":"65","author":"Rehman","year":"2016","journal-title":"Gut."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nature11053","article-title":"Human gut microbiome viewed across age and geography","volume":"486","author":"Yatsunenko","year":"2012","journal-title":"Nature."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2407.07004","article-title":"Synthetic biology-driven microbial therapeutics for disease treatment","volume":"34","author":"Kim","year":"2024","journal-title":"J Microbiol Biotechnol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioteChadv.2023.108202","article-title":"Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications","volume":"67","author":"Yu","year":"2023","journal-title":"Biotechnol Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1646897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:16:14Z","timestamp":1757650574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1646897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":147,"alternative-id":["10.3389\/fonc.2025.1646897"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1646897","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1646897"}}